Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • davisar
    Junior Member
    • Nov 2013
    • 1

    #1

    Cufflink Workflow

    I am working with 2 biological replicates and 6 sample types.

    Sample type/Biological Replicate/Drug Treatment
    A / 1 / ―
    B / 1 / ―
    C / 1 / ―
    A / 1 / +
    B / 1 / +
    C / 1 / +
    A / 2 / ―
    B / 2 / ―
    C / 2 / ―
    A / 2 / +
    B / 2 / +
    C / 2 / +

    The data was prepared using single-end Illumina deep sequencing. Data analysis is being conducted utilizing Galaxy and its tools.

    All of the original RNAseq files were preprocessed by clipping and trimming using standard parameters.

    To compare +/- drug treatment, the following procedure was undertaken:

    1. NGS: Mapping → Bowtie2

    2. NGS: RNA Analysis → Cufflinks
    a. SAM or BAM file of aligned RNA-Seq reads: Bowtie2: Aligned Reads
    b. A reference annotation and reference sequence data was utilized
    c. Bias Correction and multi-read correct were performed
    d. Reference sequence data

    3. NGS: RNA Analysis → Cuffmerge
    a. GTF file produced by Cufflinks: Cufflinks output file for sample of interest (Replicate #1_assembled transcripts)
    b. GTF file produced by Cufflinks: 2nd Cufflinks output file for sample of interest (Replicate #2_assembled transcripts)
    c. A reference annotation and reference sequence data was utilized

    4. NGS: SAM Tools → Merge BAM Files

    5. NGS: RNA Analysis → Cuffcompare compare
    a. GTF file produced by Cufflinks: 1 Cuffmerged_Combined transcripts.gtf
    b. GTF file produced by Cufflinks: 2 Cuffmerged_Combined transcripts.gtf
    c. A reference annotation and reference sequence data was utilized

    6. NGS: RNA Analysis → Cuffdiff find significant changes in transcript expression, splicing, and promoter use
    a. Transcripts: Cuffcompare_Combined transcripts.gtf
    b. Perform replicate analysis: No
    c. SAM or BAM file of aligned RNA-Seq reads: merged bam (drug treatment (-))
    d. SAM or BAM file of aligned RNA-Seq reads: merged bam (drug treatment (+))
    e. A reference annotation and reference sequence data was utilized

    Steps #3-4 were done using each pair of sample replicates (e.g., A1- & A2-; B1- & B2-; etc.). In step #5, the Cuffmerge files for + and – drug treatment were compared (e.g., (A1(-)+A2(-)) vs. (A1(+)+A2(+)), which produced a combined transcripts.gtf file that was input into step #6, Cuffdiff.

    Does this appear to be the correct work-flow to be able to compare the two groups (+/- drug treatment)? The output for Cuffdiff gene differential expression testing shows there are no significant differences between the groups; however, examining the fold change, along with the visual inspection of the alignment data using IGV, there are significant differences. I am concerned the above workflow may be “averaging-out” the significant differences.

    I considered utilized the replicate analysis option in Cuffdiff; however, I was confused as to what the correct transcript input file would be to allow for a non-biased analysis.

    Any suggestions or feedback would be greatly appreciated! Thank you advice for your time!

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
42 views
0 reactions
Last Post SEQadmin2  
Working...